SIMULTANEOUS QUANTIFICATION OF AN ANTIINFLAMMATORY COMPOUND (DUP-697) AND A POTENTIAL METABOLITE (X6882) IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

被引：7

作者：

JOSHI, AS ^{[1
]}

RAGHAVAN, N ^{[1
]}

WILLIAMS, RM ^{[1
]}

TAKAHASHI, K ^{[1
]}

SHINGU, H ^{[1
]}

KING, SYP ^{[1
]}

机构：

[1] OTSUKA PHARMACEUT FACTORY INC,DRUG METAB RES LAB,TOKUSHIMA,JAPAN

来源：

JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1994年 / 660卷 / 01期

关键词：

D O I：

10.1016/0378-4347(94)00272-X

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

A high-performance liquid chromatographic (HPLC) method using fluorescence detection has been developed for the simultaneous analysis of low nanogram concentrations of an anti-inflammatory drug, 5-Bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl] thiophene (DuP 697), and a potential metabolite (X6882) in human plasma and of DuP 697 in human urine. This assay method used an EM Separations Lichrospher C-18 endcapped column. The mobile phase was acetonitrile-water (75:25, v/v). The detection of DuP 697 and X6882 was by fluorescence at excitation and emission wavelengths of 256 and 419 nm, respectively. The chromatographic system could separate DuP 697 from X6882, the external standard (anthracene), and other endogenous substances present in human plasma. In human plasma the limits of quantification for DuP 697 and X6882 were 3 and 20 ng/ml, respectively; the limit of quantification for DuP 697 in human urine was 5 ng/ml. These compounds were shown to be stable in frozen (-20 degrees C) human plasma and urine for at least 9 weeks. The assay described has been used to characterize DuP 697 pharmacokinetics after oral administration in humans.

引用

页码：143 / 150

页数：8